Compare 3M Company (MMM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs TG Therapeutics Inc — how do they compare? 3M Company trades at $164.59 (market cap $86.39B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: 3M Company is far larger — about 10.1× TG Therapeutics Inc's market cap, and 3M Company pays a 1.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MMM | TGTX | |
|---|---|---|
Market Cap | $86.39B | $8.53B |
Sector | Industrials | Health |
52-Week High | $183.79 | $59.06 |
52-Week Low | $141.10 | $26.94 |
Enterprise Value | $95.61B | $8.74B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong recent earnings beats. The company shows solid profitability with an 11.9% net income margin and 82.77% ROE, though revenue has declined from 2022 peaks. Positive news highlights strength in transportation, electronics, and safety segments, while consumer demand remains soft.
The stock offers a balanced outlook: analyst consensus is a Buy with a $173 price target, but high debt and cost pressures pose risks. Earnings momentum from industrial growth supports upside, yet valuation multiples like a 29.75 P/E suggest limited margin for error. Investors should weigh robust fundamentals against macroeconomic and segment-specific headwinds.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
